
- Risk stratification in differentiated thyroid cancer has traditionally used a relatively small set of clinical and pathological factors to create models that predict disease-specific mortality or overall survival:
- Although clinically useful, these models provided static estimates of risk with information available within the first few months of initial therapy and demonstrated suboptimal, long-term outcome predictions for any individual patient

- Over the last decade, additional models have been developed that provide predictive information with regard to other clinically relevant outcomes, such as:
- The risk of having persistent disease after initial therapy
- The risk of structural or biochemical disease recurrence
- The likelihood of going into remission following initial therapy in adult patients with thyroid cancer

- Furthermore, rather than using information that is only available at one particular point in time, these new models emphasize the importance of dynamic risk assessment:
- Where the initial risk assessment is modified over time as new data become available
- These dynamic risk assessments allow us to:
- Integrate response to therapy assessments with the underlying individual tumor biology:
- To provide real-time risk assessments at any point in the course of the patient’s disease
- Integrate response to therapy assessments with the underlying individual tumor biology:
- Thus, the modern view of risk stratification begins with:
- The identification of a suspicious nodule (peri-diagnostic period) and continues through the phases of:
- Diagnosis
- Treatment
- Adjuvant therapy
- Follow-up
- The identification of a suspicious nodule (peri-diagnostic period) and continues through the phases of:

#Arrangoiz #ThyroidSurgeon #CancerSurgeon #HeadandNeckSurgeon #SurgicalOncologist #Teacher #Miami #MountSinaiMedicalCenter